Alogliptin / Pioglitazone Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg
Reference Brands: Oseni (USA), Incresync(EU)
Category:
Diabetes
Alogliptin/pioglitazone is an oral medication for type 2 diabetes mellitus. It combines alogliptin, a DPP-4 inhibitor, and pioglitazone, a thiazolidinedione, to help control blood sugar levels. The combination improves insulin response and reduces liver glucose production. Taken once daily, it is used when diet, exercise, or single-drug therapy is insufficient.
Alogliptin / pioglitazone Tablet is available in Tablets
and strengths such as 12.5 mg / 30 mg, 25 mg / 15 mg, 25 mg / 30 mg, 25 mg / 45 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Alogliptin / pioglitazone Tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Alogliptin / pioglitazone Tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Alogliptin / Pioglitazone is a fixed-dose combination anti-diabetic medication designed to improve glycemic control in adults with type 2 diabetes mellitus (T2D). Type 2 diabetes is a progressive condition that often requires sequential additions of therapy to maintain blood glucose levels. By combining two complementary mechanisms of action, this combination provides an effective and convenient treatment option. Alogliptin, a dipeptidyl peptidase-4 (DPP‑4) inhibitor, increases incretin activity, enhancing insulin release and suppressing glucagon secretion in a glucose-dependent manner. Pioglitazone, a thiazolidinedione, improves insulin sensitivity in peripheral tissues, helping to lower blood glucose and support long-term glycemic control.
Fixed-dose combinations like Alogliptin / Pioglitazone simplify therapy regimens, which can enhance medication adherence and improve patient outcomes. The combination is marketed globally under brand names such as Oseni and Incresync. Use of this therapy should be guided by individual patient needs, considering factors such as renal function, cardiovascular status, and potential adverse effects. Regular monitoring and collaboration with healthcare professionals ensure safe and effective management of type 2 diabetes with this combination therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing